Clinical and neurophysiological studies with the aldose reductase inhibitor, sorbinil, in symptomatic diabetic neuropathy

Abstract

The effect of sorbinil (200 mg daily for 4 weeks) was examined in 13 patients, mean age 59.7 years (range 42–72 years), with symptomatic diabetic neuropathy of mean duration 6 years (range 1–18 years). In this double-blind, placebo-controlled crossover trial, studies were made of motor, sensory and autonomic nerve function, severity of painful symptoms and… (More)
DOI: 10.1007/BF00262218

Topics

1 Figure or Table

Slides referencing similar topics